{ "run": { "id": "cmnr14kbm051yp658ls7n56hz", "region": "US", "assetId": "cmnr14kba051up658db003xle", "ticker": "MDT", "snapshotId": "cmnr14kbf051wp6583ou4799l", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:23.167Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr14kbf051wp6583ou4799l", "assetId": "cmnr14kba051up658db003xle", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 88.65, "dayLow": 86.915, "volume": 10537186, "dayHigh": 88.84, "currency": "USD", "prevClose": 86.42, "week52Low": 79.55, "week52High": 106.33 }, "fundamentals": { "pe": 23.1845730027548, "beta": 0.643015081984492, "epsTTM": 3.63, "fcfTTM": 3477000000, "growth": { "epsYoy": 0.3104693140794224, "revenueYoy": -0.7311327787220085 }, "sector": "Electromedical & Electrotherapeutic Apparatus", "margins": { "net": 0.1656348355411061, "gross": 0.1291460588662539, "operating": 0.1657040085774565 }, "website": "https://www.medtronic.com/", "industry": "Medical equipment", "pegRatio": 0.746758921135243, "ebitdaTTM": 9853000000, "forwardPe": 14.9219858156028, "marketCap": 116200000000, "totalCash": 1147000000, "totalDebt": 28071000000, "debtEquity": 0.593786440113277, "quickRatio": 1.55260663507109, "revenueTTM": 28913000000, "companyName": "Medtronic plc", "priceToBook": 2.24212732095491, "currentRatio": 2.535123749341759, "dividendYield": 0.0331712523157952, "returnOnAssets": 0.05234737935180631, "returnOnEquity": 0.0970764617691154, "analystOpinions": null, "businessSummary": "Medtronic plc is an American-Irish medical device company. The company's legal and executive headquarters are in Ireland, while its operational headquarters are in Minneapolis, Minnesota. Medtronic rebased to Ireland following its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies. It is one of the biggest medical tech companies in the world and is currently the largest medical device company in the world by revenue.", "enterpriseValue": 134494096000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 95000, "sharesOutstanding": 1283884964, "enterpriseToEbitda": 13.65006556378768, "analystTargetMedian": null, "enterpriseToRevenue": 4.651682495763152, "operatingCashflowTTM": 4757000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:23.164Z" }, "results": [ { "id": "cmnr14kbo0520p6586xbcrppu", "runId": "cmnr14kbm051yp658ls7n56hz", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MDT\",\"currency\":\"USD\",\"current_price\":88.65,\"target_price_6m\":93.0,\"target_price_12m\":96.5,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Forward P/E of ~15x is attractive for the world's largest medtech company\",\"PEG ratio of 0.75 signals undervaluation relative to expected earnings growth\",\"EPS grew 31% YoY suggesting improving operating leverage and cost discipline\",\"Dividend yield of 3.3% provides income support while awaiting re-rating\",\"Stock trades 17% below 52-week high creating entry opportunity on valuation reset\"],\"key_drivers\":[{\"driver\":\"Earnings recovery with forward EPS implying ~$5.94 vs TTM $3.63\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Medical device end-market secular growth from aging demographics\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Portfolio rationalization and margin improvement initiatives\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Revenue essentially flat YoY (-0.7%) indicating sluggish organic growth\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Significant net debt of ~$27B constraining capital allocation flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Dividend yield at 3.3% supports total return in sideways markets\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"EV/EBITDA of 13.65x is below medtech peer average of ~17x\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Tariff and trade policy uncertainty on global medical device supply chains\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Revenue stagnation persists beyond near-term as competitive threats intensify in key segments\",\"Elevated debt load limits buyback capacity and amplifies risk in a rising-rate environment\",\"GLP-1 adoption reduces demand for certain cardiovascular and diabetes devices\",\"Regulatory or reimbursement changes in major markets compress procedure volumes\",\"Macro slowdown pressures hospital capital budgets and delays elective procedures\",\"Currency headwinds from strong USD given >50% international revenue exposure\"],\"assumptions\":{\"revenue_cagr_3y\":0.04,\"ebit_margin_target\":0.22,\"wacc\":0.085,\"terminal_multiple\":15.0},\"scenarios\":{\"bear\":{\"target_price\":78.0,\"prob\":0.2,\"notes\":\"Continued revenue decline, margin compression from competition and tariffs push multiples lower.\"},\"base\":{\"target_price\":96.5,\"prob\":0.55,\"notes\":\"Moderate earnings growth realized, multiple re-rates toward 16x forward P/E on execution.\"},\"bull\":{\"target_price\":112.0,\"prob\":0.25,\"notes\":\"Pipeline catalysts and margin expansion drive EPS upside, multiple recovery toward peers.\"}},\"method_notes\":\"Blended valuation: forward P/E (16x base on ~$5.94 forward EPS ≈ $95) cross-checked with EV/EBITDA (15x on ~$10B EBITDA ≈ $97 equity value per share). Snapshot gross margin (12.9%) appears anomalous vs historical ~65%; likely a data issue—did not override snapshot. Sell-side consensus noted only as context, not used as numeric input. 12M expected return ~8.9% supports BUY. Confidence moderate due to flat revenue trajectory and macro uncertainty. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "Revenue stagnation persists beyond near-term as competitive threats intensify in key segments", "Elevated debt load limits buyback capacity and amplifies risk in a rising-rate environment", "GLP-1 adoption reduces demand for certain cardiovascular and diabetes devices", "Regulatory or reimbursement changes in major markets compress procedure volumes", "Macro slowdown pressures hospital capital budgets and delays elective procedures", "Currency headwinds from strong USD given >50% international revenue exposure" ], "ticker": "MDT", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Moderate earnings growth realized, multiple re-rates toward 16x forward P/E on execution.", "target_price": 96.5 }, "bear": { "prob": 0.2, "notes": "Continued revenue decline, margin compression from competition and tariffs push multiples lower.", "target_price": 78 }, "bull": { "prob": 0.25, "notes": "Pipeline catalysts and margin expansion drive EPS upside, multiple recovery toward peers.", "target_price": 112 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.04, "terminal_multiple": 15, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Earnings recovery with forward EPS implying ~$5.94 vs TTM $3.63", "impact": "HIGH", "direction": "POS" }, { "driver": "Medical device end-market secular growth from aging demographics", "impact": "HIGH", "direction": "POS" }, { "driver": "Portfolio rationalization and margin improvement initiatives", "impact": "MED", "direction": "POS" }, { "driver": "Revenue essentially flat YoY (-0.7%) indicating sluggish organic growth", "impact": "HIGH", "direction": "NEG" }, { "driver": "Significant net debt of ~$27B constraining capital allocation flexibility", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend yield at 3.3% supports total return in sideways markets", "impact": "MED", "direction": "POS" }, { "driver": "EV/EBITDA of 13.65x is below medtech peer average of ~17x", "impact": "MED", "direction": "POS" }, { "driver": "Tariff and trade policy uncertainty on global medical device supply chains", "impact": "MED", "direction": "NEG" } ], "method_notes": "Blended valuation: forward P/E (16x base on ~$5.94 forward EPS ≈ $95) cross-checked with EV/EBITDA (15x on ~$10B EBITDA ≈ $97 equity value per share). Snapshot gross margin (12.9%) appears anomalous vs historical ~65%; likely a data issue—did not override snapshot. Sell-side consensus noted only as context, not used as numeric input. 12M expected return ~8.9% supports BUY. Confidence moderate due to flat revenue trajectory and macro uncertainty. Not investment advice.", "current_price": 88.65, "recommendation": "BUY", "thesis_bullets": [ "Forward P/E of ~15x is attractive for the world's largest medtech company", "PEG ratio of 0.75 signals undervaluation relative to expected earnings growth", "EPS grew 31% YoY suggesting improving operating leverage and cost discipline", "Dividend yield of 3.3% provides income support while awaiting re-rating", "Stock trades 17% below 52-week high creating entry opportunity on valuation reset" ], "target_price_6m": 93, "target_price_12m": 96.5 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 35034, "createdAt": "2026-04-09T05:21:23.167Z", "usage": { "inputTokens": 3656, "outputTokens": 1727, "costUsd": 0.061455 } }, { "id": "cmnr14kbo0523p6583v95j0vz", "runId": "cmnr14kbm051yp658ls7n56hz", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"DCF_Valuation_Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"MDT\",\n \"currency\": \"USD\",\n \"current_price\": 88.65,\n \"target_price_6m\": 92.0,\n \"target_price_12m\": 95.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Medtronic shows stable growth in medical devices.\",\n \"Margin expansion from operational efficiencies expected.\",\n \"Strong free cash flow supports shareholder returns.\",\n \"Innovation pipeline could drive future revenue.\",\n \"Valuation appears reasonable with upside potential.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Product innovation\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory approvals\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Healthcare spending trends\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Competition intensity\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Economic cycles\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Currency fluctuations\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Aging population demand\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Pricing pressure\", \"impact\": \"MED\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\n \"Regulatory delays or rejections.\",\n \"Intense competition from peers.\",\n \"Macroeconomic downturn affecting healthcare budgets.\",\n \"Supply chain disruptions.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.03,\n \"ebit_margin_target\": 0.17,\n \"wacc\": 0.075,\n \"terminal_multiple\": 14.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 80.0, \"prob\": 0.2, \"notes\": \"Slower growth or regulatory issues.\" },\n \"base\": { \"target_price\": 95.0, \"prob\": 0.6, \"notes\": \"Moderate growth and margin expansion.\" },\n \"bull\": { \"target_price\": 110.0, \"prob\": 0.2, \"notes\": \"Faster adoption of new products.\" }\n },\n \"method_notes\": \"Used DCF with assumed 3% revenue growth, 17% EBIT margin, 7.5% WACC, 14x terminal multiple. ~7% upside implies BUY. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "DCF_Valuation_Model", "risks": [ "Regulatory delays or rejections.", "Intense competition from peers.", "Macroeconomic downturn affecting healthcare budgets.", "Supply chain disruptions." ], "ticker": "MDT", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Moderate growth and margin expansion.", "target_price": 95 }, "bear": { "prob": 0.2, "notes": "Slower growth or regulatory issues.", "target_price": 80 }, "bull": { "prob": 0.2, "notes": "Faster adoption of new products.", "target_price": 110 } }, "confidence": 0.65, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.03, "terminal_multiple": 14, "ebit_margin_target": 0.17 }, "key_drivers": [ { "driver": "Product innovation", "impact": "HIGH", "direction": "POS" }, { "driver": "Regulatory approvals", "impact": "MED", "direction": "POS" }, { "driver": "Healthcare spending trends", "impact": "MED", "direction": "POS" }, { "driver": "Competition intensity", "impact": "HIGH", "direction": "NEG" }, { "driver": "Economic cycles", "impact": "LOW", "direction": "NEG" }, { "driver": "Currency fluctuations", "impact": "MED", "direction": "NEG" }, { "driver": "Aging population demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Pricing pressure", "impact": "MED", "direction": "NEG" } ], "method_notes": "Used DCF with assumed 3% revenue growth, 17% EBIT margin, 7.5% WACC, 14x terminal multiple. ~7% upside implies BUY. Not investment advice.", "current_price": 88.65, "recommendation": "BUY", "thesis_bullets": [ "Medtronic shows stable growth in medical devices.", "Margin expansion from operational efficiencies expected.", "Strong free cash flow supports shareholder returns.", "Innovation pipeline could drive future revenue.", "Valuation appears reasonable with upside potential." ], "target_price_6m": 92, "target_price_12m": 95 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 457, "createdAt": "2026-04-09T05:21:23.167Z", "usage": { "inputTokens": 2160, "outputTokens": 4575, "costUsd": 0.002526 } }, { "id": "cmnr14kbo0521p658t5t8n9xy", "runId": "cmnr14kbm051yp658ls7n56hz", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch_Fundamental_Defensive\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"MDT\",\n \"currency\": \"USD\",\n \"current_price\": 88.65,\n \"target_price_6m\": 93.00,\n \"target_price_12m\": 98.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.7,\n \"thesis_bullets\": [\n \"Attractive forward valuation (14.9x P/E) limits downside risk for this defensive medtech giant.\",\n \"Strong pipeline in cardiovascular and neuroscience segments supports mid-single-digit underlying growth.\",\n \"Solid 3.3% dividend yield provides a reliable income floor during market volatility.\",\n \"Margins are pressured by inflation and FX, but cost-cutting initiatives are taking effect.\",\n \"The reported revenue drop reflects portfolio restructuring, masking stable core business demand.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Cardiovascular portfolio growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Hugo robotic-assisted surgery adoption\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Hospital capital equipment spending\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"FX headwinds from strong USD\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Supply chain stabilization\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Diabetes segment recovery\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"GLP-1 impact on bariatric/cardio TAM\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Slower-than-expected adoption of the Hugo robotic surgery system.\",\n \"Persistent inflation and supply chain disruptions compressing gross margins.\",\n \"GLP-1 weight-loss drugs reducing long-term demand for cardiovascular and diabetes interventions.\",\n \"Foreign exchange headwinds due to significant international revenue exposure.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.04,\n \"ebit_margin_target\": 0.22,\n \"wacc\": 0.075,\n \"terminal_multiple\": 15.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 75.0,\n \"prob\": 0.2,\n \"notes\": \"Hospital capex freezes and GLP-1 fears materialize, compressing multiples.\"\n },\n \"base\": {\n \"target_price\": 99.0,\n \"prob\": 0.6,\n \"notes\": \"Steady mid-single-digit growth and margin recovery drive multiple expansion to 16x forward P/E.\"\n },\n \"bull\": {\n \"target_price\": 118.0,\n \"prob\": 0.2,\n \"notes\": \"Hugo robotics adoption accelerates and diabetes segment regains major market share.\"\n }\n },\n \"method_notes\": \"Valuation based on a 10-year DCF and forward P/E multiple of 16x. Probability-weighted scenarios yield a 12M target of $98, implying ~10.5% upside. Recommendation is BUY. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "EquityResearch_Fundamental_Defensive", "risks": [ "Slower-than-expected adoption of the Hugo robotic surgery system.", "Persistent inflation and supply chain disruptions compressing gross margins.", "GLP-1 weight-loss drugs reducing long-term demand for cardiovascular and diabetes interventions.", "Foreign exchange headwinds due to significant international revenue exposure." ], "ticker": "MDT", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady mid-single-digit growth and margin recovery drive multiple expansion to 16x forward P/E.", "target_price": 99 }, "bear": { "prob": 0.2, "notes": "Hospital capex freezes and GLP-1 fears materialize, compressing multiples.", "target_price": 75 }, "bull": { "prob": 0.2, "notes": "Hugo robotics adoption accelerates and diabetes segment regains major market share.", "target_price": 118 } }, "confidence": 0.7, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.04, "terminal_multiple": 15, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Cardiovascular portfolio growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Hugo robotic-assisted surgery adoption", "impact": "MED", "direction": "POS" }, { "driver": "Hospital capital equipment spending", "impact": "HIGH", "direction": "NEG" }, { "driver": "FX headwinds from strong USD", "impact": "MED", "direction": "NEG" }, { "driver": "Supply chain stabilization", "impact": "MED", "direction": "POS" }, { "driver": "Diabetes segment recovery", "impact": "MED", "direction": "POS" }, { "driver": "GLP-1 impact on bariatric/cardio TAM", "impact": "MED", "direction": "NEG" } ], "method_notes": "Valuation based on a 10-year DCF and forward P/E multiple of 16x. Probability-weighted scenarios yield a 12M target of $98, implying ~10.5% upside. Recommendation is BUY. Not investment advice.", "current_price": 88.65, "recommendation": "BUY", "thesis_bullets": [ "Attractive forward valuation (14.9x P/E) limits downside risk for this defensive medtech giant.", "Strong pipeline in cardiovascular and neuroscience segments supports mid-single-digit underlying growth.", "Solid 3.3% dividend yield provides a reliable income floor during market volatility.", "Margins are pressured by inflation and FX, but cost-cutting initiatives are taking effect.", "The reported revenue drop reflects portfolio restructuring, masking stable core business demand." ], "target_price_6m": 93, "target_price_12m": 98 }, "errorsJson": { "attempts": [ { "error": "sanity_error: buy_scenario_return_too_low: BUY requires >= 6% return from probability-weighted scenarios.", "attempt": 0, "rawOutputTruncated": "{\n \"model\": \"EquityResearch_Fundamental_Defensive\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"MDT\",\n \"currency\": \"USD\",\n \"current_price\": 88.65,\n \"target_price_6m\": 93.00,\n \"target_price_12m\": 98.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.70,\n \"thesis_bullets\": [\n \"Attractive forward valuation (14.9x P/E) limits downside risk for this defensive medtech giant.\",\n \"Strong pipeline in cardiovascular and neuroscience segments supports mid-single-digit underlying growth.\",\n \"Solid 3.3% dividend yield provides a reliable income floor during market volatility.\",\n \"Margins are pressured by inflation and FX, but cost-cutting initiatives are taking effect.\",\n \"The reported revenue drop reflects portfolio restructuring, masking stable core business demand.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Cardiovascular portfolio growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Hugo robotic-assisted surgery adoption\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Hospital capital equipment spending\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"FX headwin…" } ], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 22151, "createdAt": "2026-04-09T05:21:23.167Z", "usage": { "inputTokens": 3179, "outputTokens": 885, "costUsd": 0.016978 } }, { "id": "cmnr14kbo051zp658er75tfdi", "runId": "cmnr14kbm051yp658ls7n56hz", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MDT\",\"currency\":\"USD\",\"current_price\":88.65,\"target_price_6m\":90.5,\"target_price_12m\":92,\"recommendation\":\"HOLD\",\"confidence\":0.59,\"thesis_bullets\":[\"Defensive medtech franchise supports resilient cash flow and dividend.\",\"Forward P/E looks reasonable, but leverage limits multiple expansion.\",\"Product launches can lift growth, yet execution remains uneven.\",\"Mixed reported revenue trend increases forecasting uncertainty.\",\"Risk-reward appears balanced with shares near fair value.\"],\"key_drivers\":[{\"driver\":\"Procedure volume recovery\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Diabetes franchise adoption\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"New product approvals\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Margin expansion programs\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"FX translation headwinds\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Hospital budget pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Recall or compliance events\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Deleveraging and capital returns\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Procedure growth slows further\",\"Product recall or warning letter\",\"FX and international demand pressure\",\"Higher rates sustain valuation pressure\",\"Execution misses in diabetes or robotics\"],\"assumptions\":{\"revenue_cagr_3y\":4.5,\"ebit_margin_target\":19,\"wacc\":7.8,\"terminal_multiple\":15.5},\"scenarios\":{\"bear\":{\"target_price\":78,\"prob\":0.25,\"notes\":\"Growth stalls and margins fail to improve.\"},\"base\":{\"target_price\":92,\"prob\":0.5,\"notes\":\"Mid-single-digit growth and modest margin expansion.\"},\"bull\":{\"target_price\":104,\"prob\":0.25,\"notes\":\"Pipeline execution and margins beat expectations.\"}},\"method_notes\":\"Snapshot quote/fundamentals used as baseline. PTs blend a normalized 15.5x earnings/EV-EBIT view with 4.5% revenue CAGR and 19% EBIT margin; cross-checked to dividend support and leverage. Snapshot revenueYoY appears distorted, lowering confidence. No sell-side targets used; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Model Recommendation", "risks": [ "Procedure growth slows further", "Product recall or warning letter", "FX and international demand pressure", "Higher rates sustain valuation pressure", "Execution misses in diabetes or robotics" ], "ticker": "MDT", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Mid-single-digit growth and modest margin expansion.", "target_price": 92 }, "bear": { "prob": 0.25, "notes": "Growth stalls and margins fail to improve.", "target_price": 78 }, "bull": { "prob": 0.25, "notes": "Pipeline execution and margins beat expectations.", "target_price": 104 } }, "confidence": 0.59, "assumptions": { "wacc": 7.8, "revenue_cagr_3y": 4.5, "terminal_multiple": 15.5, "ebit_margin_target": 19 }, "key_drivers": [ { "driver": "Procedure volume recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Diabetes franchise adoption", "impact": "HIGH", "direction": "POS" }, { "driver": "New product approvals", "impact": "HIGH", "direction": "POS" }, { "driver": "Margin expansion programs", "impact": "MED", "direction": "POS" }, { "driver": "FX translation headwinds", "impact": "MED", "direction": "NEG" }, { "driver": "Hospital budget pressure", "impact": "MED", "direction": "NEG" }, { "driver": "Recall or compliance events", "impact": "HIGH", "direction": "NEG" }, { "driver": "Deleveraging and capital returns", "impact": "LOW", "direction": "POS" } ], "method_notes": "Snapshot quote/fundamentals used as baseline. PTs blend a normalized 15.5x earnings/EV-EBIT view with 4.5% revenue CAGR and 19% EBIT margin; cross-checked to dividend support and leverage. Snapshot revenueYoY appears distorted, lowering confidence. No sell-side targets used; not investment advice.", "current_price": 88.65, "recommendation": "HOLD", "thesis_bullets": [ "Defensive medtech franchise supports resilient cash flow and dividend.", "Forward P/E looks reasonable, but leverage limits multiple expansion.", "Product launches can lift growth, yet execution remains uneven.", "Mixed reported revenue trend increases forecasting uncertainty.", "Risk-reward appears balanced with shares near fair value." ], "target_price_6m": 90.5, "target_price_12m": 92 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0838e7817ca384d20069d75b42078c8190a22de5bb7616b9b6", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 33097, "createdAt": "2026-04-09T05:21:23.167Z", "usage": { "inputTokens": 2432, "outputTokens": 1613, "costUsd": 0.026838 } }, { "id": "cmnr14kbo0522p658wsi10pa9", "runId": "cmnr14kbm051yp658ls7n56hz", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Fundamental Valuation Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"MDT\",\n \"currency\": \"USD\",\n \"current_price\": 88.65,\n \"target_price_6m\": 90.0,\n \"target_price_12m\": 93.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Global leader in medical devices with strong brand\",\n \"Stable FCF supports 3.3% dividend yield\",\n \"Recent revenue growth impacted by market factors\",\n \"Innovation in CV and diabetes offers upside\",\n \"Valuation at 15x forward P/E appears fair\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Aging population and chronic diseases\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"R&D pipeline in diabetes and CV\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Margin expansion initiatives\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Intense competition in medtech\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Regulatory approval delays\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Healthcare spending and reimbursement\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Foreign currency fluctuations\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Supply chain and manufacturing costs\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Pricing pressures from hospitals and payers\",\n \"Product recalls or quality issues\",\n \"Slower procedure volumes recovery\",\n \"Geopolitical risks affecting global ops\",\n \"Patent expirations on key products\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.045,\n \"ebit_margin_target\": 0.22,\n \"wacc\": 0.085,\n \"terminal_multiple\": 16.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 75.0,\n \"prob\": 0.3,\n \"notes\": \"Persistent headwinds lead to lower growth and multiples.\"\n },\n \"base\": {\n \"target_price\": 93.0,\n \"prob\": 0.5,\n \"notes\": \"Moderate growth and stable margins align with expectations.\"\n },\n \"bull\": {\n \"target_price\": 115.0,\n \"prob\": 0.2,\n \"notes\": \"Strong execution and new product success drive upside.\"\n }\n },\n \"method_notes\": \"DCF model using 4.5% 3Y revenue CAGR to reach target EBIT margins, 8.5% WACC and 16.5x terminal EV/EBITDA. Mixed evidence on growth trajectory supports HOLD. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Fundamental Valuation Model", "risks": [ "Pricing pressures from hospitals and payers", "Product recalls or quality issues", "Slower procedure volumes recovery", "Geopolitical risks affecting global ops", "Patent expirations on key products" ], "ticker": "MDT", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Moderate growth and stable margins align with expectations.", "target_price": 93 }, "bear": { "prob": 0.3, "notes": "Persistent headwinds lead to lower growth and multiples.", "target_price": 75 }, "bull": { "prob": 0.2, "notes": "Strong execution and new product success drive upside.", "target_price": 115 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.045, "terminal_multiple": 16.5, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Aging population and chronic diseases", "impact": "HIGH", "direction": "POS" }, { "driver": "R&D pipeline in diabetes and CV", "impact": "HIGH", "direction": "POS" }, { "driver": "Margin expansion initiatives", "impact": "MED", "direction": "POS" }, { "driver": "Intense competition in medtech", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory approval delays", "impact": "MED", "direction": "NEG" }, { "driver": "Healthcare spending and reimbursement", "impact": "HIGH", "direction": "POS" }, { "driver": "Foreign currency fluctuations", "impact": "MED", "direction": "NEG" }, { "driver": "Supply chain and manufacturing costs", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF model using 4.5% 3Y revenue CAGR to reach target EBIT margins, 8.5% WACC and 16.5x terminal EV/EBITDA. Mixed evidence on growth trajectory supports HOLD. Not investment advice.", "current_price": 88.65, "recommendation": "HOLD", "thesis_bullets": [ "Global leader in medical devices with strong brand", "Stable FCF supports 3.3% dividend yield", "Recent revenue growth impacted by market factors", "Innovation in CV and diabetes offers upside", "Valuation at 15x forward P/E appears fair" ], "target_price_6m": 90, "target_price_12m": 93 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "377f38db-e427-90e7-b8a5-7e2775ed40ac", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 22340, "createdAt": "2026-04-09T05:21:23.167Z", "usage": { "inputTokens": 2766, "outputTokens": 3519, "costUsd": 0.061083 } } ] } }